Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity

Journal of Immunology

Volumn 166, Issue 10, 2001, Pages 6112-6117

  McCall, Adrian M ^a   Shahied, Lillian ^a   Amoroso, Anne R ^a   Horak, Eva M ^a   Simmons, Heidi H ^a   Nielson, Ulrick ^b   Adams, Gregory P ^a   Schier, Robert ^a,c   Marks, James D ^b   Weiner, Louis M ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Xerion Pharmaceuticals AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD16 ANTIGEN; CHROMIUM 51; IMMUNOGLOBULIN FC FRAGMENT; TUMOR ANTIGEN;

ANTIBODY SPECIFICITY; ANTIBODY STRUCTURE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CALCIUM MOBILIZATION; CONTROLLED STUDY; CROSS LINKING; CYTOLYSIS; CYTOTOXICITY; HUMAN; HUMAN CELL; NATURAL KILLER CELL; ONCOGENE NEU; PRIORITY JOURNAL;

EID: 0035873188     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.10.6112     Document Type: Article

References (43)

1. Deo, Y. M., R. F. Graziano, R. Repp, and. J. G. J. van de Winkel. 1997. Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies. Immunol. Today 18:127.
2. Kaminski, M. S., K. R. Zasady, I. R. Francis, A. W. Milik, C. W. Ross, S. D. Moon, S. M. Crawford, J. M. Burgess, N. A. Petry, G. M. Butchko, G. D. Glenn, and R. L. Wahl. 1993. Radioimmunotherapy of B-cell lymphoma with 1311-anti-B1 (anti-CD20) antibody. N. Engl. J. Med. 329:459.
3. Siever, E. L., I. D. Berstein, R. T. Spielberger, S. J. Forman, M. S. Berger, K. Shannon-Dorcy, and F. R. Appelbaum. 1997. Dose escalation phase I study of recombinant engineered human anti-CD33 antibody-calicheamicin drug conjugate (CMA-676) in patients with relapsed or refractory acute myeloid leukemia (AML). Proc. Am. Soc. Clin. Oncol. 16:A8.
4. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14:737.
5. +/MBC) markedly increased anticancer activity: a randomized, multinational controlled Phase III trial. Proc. Am. Soc. Clin. Oncol. 17:A377.
6. Weiner, L. M., Z. Steplewski, and H. Koprowski. 1986. Biologic effects of γ interferon pretreatment followed by monoclonal antibody 17-1A administration in patients with gastrointestinal carcinoma. Hybridoma 5:65.
7. Vadhan-Raj, S., C. Cordon-Cardo, E. Carswell, D. Mintzer, L. Dantis, C. Duteau, M. A. Templeton, H. F. Oettgen, L. J. Old, and A. N. Houghton. 1988. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J. Clin. Oncol. 6:1636.
8. Shen, L., P. M. Guyre, C. L. Anderson, and M. W. Fanger. 1986. Heteroantibody-mediated cytotoxicity: antibody to the high affinity Fc receptor for IgG mediates cytotoxicity by human monocytes that is enhanced by interferon-γ and is not blocked by human IgG. J. Immunol. 137:3378.
9. Garcia de Palazzo, I., C. Gercel-Taylor, J. Kitson, and L. M. Weiner. 1990. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fcγ receptor expressed by human large granular lymphocytes. Cancer Res. 50:7123.
10. Weiner, L. M., M. Holmes, A. Richeson, A. Godwin, G. P. Adams, S. T. Hsieh-Ma, D. B. Ring, and R. K. Alpaugh. 1993. Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. J. Immunol. 151:2877.
11. Hsieh-Ma, S. T., A. M. Eaton, T. Shi, and D. B. Ring. 1992. In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1, recognizing c-erbB-2 protooncogene product and Fcγ receptor III. Cancer Res. 52:6832.
12. Sconocchia, G., J. A. Titus, and D. M. Segal. 1994. CD44 is a cytotoxic triggering molecule in human peripheral blood NK cells. J. Immunol. 153:5473.
13. Segal, D. M., and J. Wunderlich. 1988. Targeting of cytotoxic cells with heterocrosslinked antibodies. Cancer Invest. 6:83.
14. Renner, C., Jung, W., U. Sahin, R. van Lier, and M. Pfreundschuh. 1995. The role of lymphocyte subsets and adhesion molecules in T-cell-dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies. Eur. J. Immunol. 25:2027.
15. Fanger, M. W., L. Shen, R. F. Graziano, and P. M. Guyre. 1989. Cytotoxicity mediated by human Fc receptors for IgG. Immunol. Today 10:92.
16. Shi, T., A. M. Eaton, and D. B. Ring. 1991. Selection of hybrid hybridomas by flow cytometry using a new combination of fluorescent vital stains. J. Immunol. Methods 141:165.
17. Huston, J. S., M. Mudgett-Hunter, T. Mei-Sheng, J. McCartney, F. Warren, E. Haber, and H. Opperman. 1991. Protein engineering of single-chain Fv analogs and fusion proteins. Methods Enzymol. 203:46.
18. Gruber, M., B. A. Schodin, E. R. Wilson, and D. M. Kranz. 1994. Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. J. Immunol. 152:5368.
19. George, A. J., J. A. Titus, C. R. Jost, I. Kurucz, P. Perez, S. M. Andrew, P. J. Nicholls, and D. M. Segal. 1994. Redirection of T-cell mediated cytotoxicity by a recombinant single chain-Fv molecule. J. Immunol. 152:1802.
20. Weiner, G. J., S. A. Kostelny, J. R. Hillstrom, M. S. Cole, B. K. Link, S. L. Wang, and J. Y. Tso. 1994. The role of T cell activation in anti-CD3 × antitumor bispecific antibody therapy. J. Immunol. 152:2385.
21. McCall, A. M., G. P. Adams, A. R. Amoroso, U. B. Nielsen, L. Zhang, E. Horak, H. Simmons, R. Schier, J. D. Marks, and L. M. Weiner. 1999. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Mol. Immunol. 36:433.
22. Valone, F. H., P. A. Kaufman, P. M. Guyre, L. D. Lewis, V. Memolli, Y. Deo, R. Graziano, J. L. Fisher, L. Meyer, and M. Mrozek-Orlowski. 1995. Phase Ia/Ib trial of bispecific antibody MDX-210 (anti-HER-2/neu × anti-FcγRI) in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J. Clin. Oncol. 13:2281.
23. Nitta, T., K. Sato, H. Yagita, K. Okumura, and S. Ishii. 1990. Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335:368.
24. Katayose, Y., T. Kudo, M. Suzuki, M. Shinoda, S. Saijyo, N. Sakurai, H. Saeki, K. Fukuhara, K. Imai, and S. Matsuno. 1996. MUC-1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth. Cancer Res. 56:4205.
25. Weiner, L. M., L. L. Houston, J. S. Huston, J. E. McCartney, M. S. A. Tai, G., W. F. Stafford, M. A. Bookman, J. M. Gallo, and G. P. Adams. 1995. Improving the tumor-selective delivery of single-chain Fv molecules. Tumor Targeting 1:51.
26. van Ojik, H. H., R. Repp, G. Groenewegen, T. Valerius, and, J. G. van de Winkel. 1997. Clinical evaluation of the bispecific antibody MDX-H210(anti-FcγRI × anti HER2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer. Cancer Immunol. Immunother. 45:207.
27. Bolhuis, R. L., C. H. Lamers, S. H. Goey, A. M. Eggermont, J. B. Trimbos, G. Stoter, A. Lanzavecchia, E. di Re, S. Miotti, and F. Raspagliesi. 1992. Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. Int. J. Cancer Suppl. 7:78.
28. Weiner, L. M., M. Holmes, G. P. Adams, F. LaCreta, P. Watts, and I. G. De Palazzo. 1993. A human tumor xenograft model of therapy with a bispecific monoclonal antibody c-erbB-2 and CD16. Cancer Res. 53:94.
29. Weiner, L. M., R. K. Alpaugh, A. R. Amoroso, C. P. Adams, D. B. Ring, and M. W. Barth. 1996. Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human FcγRIII. Cancer Immunol. Immunother. 42:141.
30. Schier, R., J. D. Marks, E. Wolf, G. Apell, C. Wong, J. McCartney, M. Bookman, J. Huston, L. Weiner, and G. Adams. 1995. In vitro and in vivo characterization of a human anti-c-erB2 single chain Fv isolated from a filamentous phage antibody library. Immunotechnology 1:73.
31. de Wildt, R. M. T., R. Finnern, W. H. Ouwehand, A. D. Griffiths, W. J. Van Venrooij, and R. M. A. Hoet. 1996. Characterization of human variable domain antibody fragments against the U1-RNA-associated A protein, selected from a synthetic and a patient-derived combinatorial V gene library. Eur. J. Immunol. 26:629.
32. Johnsson, B., S. Löfås, and G. Lindqvist. 1991. Immobilization of proteins to a carboxymethyldextran modified gold surface for BIAcore in surface plasmon resonance. Anal. Biochem. 198:268.
33. Novak, E. J., and P. S. Rabinovitch. 1994. Improved sensitivity in flow cytometric intracellular ionized calcium measurement using fluo-3/Fura Red fluorescence ratios. Cytometry 17:135.
34. Clark, J. I., R. K. Alpaugh, M. von Mehren, J. Schultz, J. R. Gralow, M. A. Cheever, D. B. Ring, and L. M. Weiner. 1997. Induction of multiple anti-c-erbB2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment. Cancer Immunol. Immunother. 44:265.
35. Vossebeld, P. J. M., C. H. E. Homberg, D. Roos, and A. J. Verhoeven. 1997. The anti-FcγRIII Mab 3G8 induces neutrophil activation via a cooperative action of FcγRIIIb and FcγRIIa. Int. J. Biochem. Cell Biol. 29:465.
36. Mallender, W. D., and E. W. Voss. 1994. Construction, expression and activity of a bispecific single-chain antibody. J. Biol. Chem. 269:199.
37. Helfrich, W., B. J. Kroeson, R. C. Roovers, L. Westers, G. Molema, H. R. Hoggenboom, and L. de Leij. 1998. Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas. Int. J. Cancer 76:232.
38. Schier, R., A. McCall, G. P. Adams, K. W. Marshall, H. Merritt, M. Yim, R. S. Crawford, L. M. Weiner, C. Marks, and J. D. Marks. 1996. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J. Mol. Biol. 263:551.
39. McCall, A. M., A. R. Amoroso, C. Sautes, J. D. Marks, and L. M. Weiner. 1998. Characterization of anti-mouse FcγRII single-chain Fv fragments derived from human phage display libraries. Immunotechnology 4:71.
40. Kranz, D. M., M. Gruber, and E. R. Wilson. 1995. Properties of bispecific single chain antibodies expressed in Escherichia coli. J. Hematother. 4:403.
41. HER2 overexpressing tumor cells. Int. J. Cancer 62:319.
42. Adams, G. P., R. Schier, K. Marshall, E. J. Wolf, A. M. McCall, J. D. Marks, and L. M. Weiner. 1998. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 58:485.
43. Juweid, M., R. Neumann, C. Paik, M. J. Perez-Bacete, J. Sato, W. van Osdol, and J. N. Weinstein. 1992. Micropharmacology of monoclonal antibodies in solid minors: direct experimental evidence for a binding site barrier. Cancer Res. 52:5144.